BioCatalystWatch
URGNWorkspace / URGN / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026UGN-103 — LONGVIEW-HR, adjuvant therapy versus gemcitabine · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

UGN-103

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

UGN-103

PreINDP1P2FilingApproved
Upcoming / outlook

UGN-103

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

UGN-103

PreINDP1P2FilingApproved
Upcoming / outlook

UGN-103

Upcoming / outlook

UGN-103

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

Partner / License out

PreINDP1P2P3FilingApproved

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

History / paused

CTLA-4

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

URGN SEC archive